‘This is an IoT device if there ever was one’
PLANO, Texas – The SensoSCAN vital sign monitor from Sensogram Technologies is in the final phases of development and is ready to shake up the market later this month.
SensoSCAN is a continuous, non-invasive, wireless, integrated vital sign monitor for the assisted living, PERS, elderly remote patient monitoring and home wellness markets. Sensogram will launch a fall detection wristband in April, followed by a ring that monitors an exhaustive list of vital signs by mid-year.
“SensoSCAN is a better tool to take patient monitoring to the next level,” said Pete Ianace, Sensogram corporate development director. “From a pure market perspective, this is an Internet of Things, big data device if there ever was one.”
SensoSCAN monitors blood pressure, respiration, heart rate and oxygen saturation in real time through a single wearable device. Users can monitor and share their vitals with caregivers, family members and physicians through smartphone apps and a website portal.
“We are proud to introduce an easy-to-use, non-invasive wearable device that can continuously monitor blood pressure,” said Dr. Vahram Mouradian, founder and CEO of Sensogram. ” The ability to share real-time vitals data with those with a need to know will help manage known chronic illnesses or even help prevent their onset. This is because the data stream is continuous and not just a spot check done a few times a year with a blood pressure cuff.”
The device collects the data 512 times per second, then filters and stores it for analysis at a later date.
“The data can be used to predict things like a heart attack or stroke, which increases a patient’s chance of survival,” Ianace said.
Sensogram is confident that SensoSCAN will simplify a process that historically has been complicated, improving health care and patient outcomes.
“No one else has been able to do non-invasive, real-time blood pressure monitoring until now,” said Ianace. “This is big data collection at the human level.”
Ianace said the first 30,000 units of SensoSCAN will be pushed to its four targeted markets, then the company will then begin looking at expanding out.
Ianace said Sensogram also plans on licensing the platform to third parties.
“There are big opportunities for telehealth, long-term disease management and post-surgical discharge,” said Ianace.
Ianace said the device should receive approval from the U.S. Food and Drug Administration soon, as well as CE Mark certification.